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ABSTRACT 
Objective: The objective of this work was to improve the solubility and dissolution rate of Nifedipine by preparing a solid-self micro emulsifying 
drug delivery system (Solid-smedds).  
Methods: Liquid-self-emulsifying drug delivery system formulations were prepared by using linseed oil as oil, tween 80 as a surfactant and PEG 
400 as cosurfactant. Components were selected by solubility screening studies and the self-emulsifying region was identified by the pseudo-ternary 
phase diagram. Thermodynamic stability study was performed for the determination of stable liquid-smedds formulation. These formulations were 
evaluated for self-emulsification time, drug content analysis, robustness to dilution test, particle size analysis, in vitro diffusion study, and Stability 
study. Solid self-micro emulsifying formulations were prepared by using aerosil-200 at a different ratio. Lf9S (0.65:1) was selected due to its highest 
drug entrapment efficiency and a decrease in particle size. It was selected for further studies into DSC, SEM, FTIR, and XRD analysis. 
Results: DSC and XRD result shows that the drug within the formulation was in the amorphous state. From the SEM study, it was observed that the 
drug has been uniformly distributed and having a smooth surface. From the in vitro dissolution study, it improved the dissolution rate of nifedipine 
which was 98.70% of drug release where pure drug release only 6.72%.  
Conclusion: In conclusion, a solid self-micro emulsifying drug delivery system is improved the solubility and drug release rate but also improved 
the stability of the formulation.  
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INTRODUCTION 
Around 40% of recent drug candidates become poor water solubility 
and also the oral deliveries of those medicines are usually related to 
high intrasubject and inter-subject variability, a lack of dose 
proportionality, low bioavailability. To overcome these issues, 
several formulation ways are utilized together with specific 
utilization of surfactants, lipids, permeation enhancers, 
micronization, salt formation, cyclodextrins, solid dispersion. Newly, 
the lipid-based formulation has gained a lot of attention with special 
importance on self-emulsifying drug delivery systems (SEDDS) 
which is used to boost the bioavailability of orally administered 
lipophilic drugs. SEDDS or self-emulsifying oil formulations (Seof) 
outlined as isotropic mixtures of natural or synthetic oils, solid or 
liquid surfactants or instead, one or additional hydrophilic solvents 
and co-solvents/surfactants [1]. On delicate agitation, these systems 
will form fine o/w emulsions (oil-in-water) or self-micro emulsifying 
drug delivery system (SMEDDS) or microemulsions followed with 
dilution into liquid media, like epithelial duct (GI) fluids [2]. SEDDS 
effectively produce emulsions with a droplet size range of 100-200 
nm for SMEDDS whereas SNEDDS produce less than 100 nm [3]. 
Nifedipine is a dihydropyridine calcium channel antagonist that 
belongs to BCS class-II mainly applied in the treatment of 
hypertension and angina-pectoris administered by the oral route. It 
is the most common kind of calcium channel blocker (CCB) and is 
used for the treatment of hypertension as well as stable, unstable 
and prinzmetal angina. It is known to exhibit its antihypertensive 
effect at a very low plasma concentration of 13.4 mg/ml [5]. Taneja 
et al. [4] had developed a pulsatile microsphere of nifedipine for the 
treatment of hypertension. It showed slow release of drug initially 
for 4 h. and at a particular lag time, it followed pulsatile release 
(after 6 h). In recent studies, nifedipine in combination with 
Valsartan and Candesartan lowers blood pressure effects in high-
risk individuals. Mancia et al. had examined the effects of nifedipine 
GITS–candesartan cilexetil combination at various doses. This 
combination therapy has been proved that the effect of blood 
pressure was lowered as well as decrease the incidence of 
vasodilatory side effects [5]. Another achievement for the 
development of a microemulsion system of nifedipine and valsartan 
which was administered transdermally invitro(rat skin) to observe 
the permeation rate. The study was suggested that the 
microemulsion system improved the solubilization as well as 
transportation of both drugs across rate skin [6].  
On another side, nifedipine is used in the treatment of angina, but at 
high doses, nifedipine increased the risk of out of hospital cardiac 
arrest due to fatal cardiac arrhythmia [7]. Another important aspect 
has been reported that nifedipine can promote breast cancer and 
should be avoided for women who suffer from breast cancer and 
hypertension. From the report, it was identified that the effects of 
nifedipine on MCF-7 cells were via the protein kinase B-endothelial 
constitutive nitric oxide synthase-nitric oxide axis, and on MDA-MB-
231 cells via activation of the extracellular signal-regulated kinase 
pathway [8].  
In this study, an attempt was made to improve the solubility and in 
vitro dissolution of nifedipine by formulating it as S-SMEDDS. 
Nifedipine, Dimethyl 2, 6-dimethyl-4-(2-nitrophenyl)-1, 4 
dihydropyridine-3,5-dicarboxylate, has poor aqueous solubility 
resulting in low and often irregular bioavailability. The present work 
provided in improvement in the dissolution rate for nifedipine when 
formulated as self-emulsifying drug delivery systems. The self-
emulsifying mixture that combines good self-emulsifying properties, 
acceptable solubilization of nifedipine and optimum surfactant, co-
surfactant/co-solvent composition was selected, evaluated for 
droplet size, stability, dissolution, and a Solid SMEDDS was prepared 
using aerosil 200 as adsorbent. The solid SMEDDS was further 
evaluated by in vitro dissolution studies and characterized by 
Scanning electron microscopy (SEM), Differential scanning 
calorimetry (DSC) and Fourier transform infrared spectroscopy (FT-
IR). 
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Drug release is a vital and rate-limiting step, mainly for drugs with 
low solubility and high permeability i.e., biopharmaceutical 
classification system BCS class II drugs. SEDDS is the technique that 
can be used to enhance the solubility and dissolution rate of poorly 
water-soluble drugs. 
But Liquid SEDDS having problems like the irritating effect of a high 
percentage of surfactant on the gastrointestinal mucosa, lower 
formulation stability and plausible interaction of excipients with 
capsule shell. To surmount these ostensible problems associated 
with liquid SEDDS a new technology is investigated known as solid 
S-SEDDS [9, 10]. 
Solid SEDDS are the solidified self-emulsifying formulation which is 
prepared by converting liquid/semisolid SEDDS into self-
emulsifying powders/nanoparticles by using various solidification 
techniques such as, nanoparticle technology, melt extrusion, spray 
drying, and adsorptions to solid carriers [11]. 
MATERIALS AND METHODS 
Materials 
Nifedipine was a gift sample from G. C. Chemie Pharmie Ltd; 
Mumbai, India. Almond oil, Soybean oil, castor oil, and linseed oil 
were supplied by Merck Pvt. Ltd. Tween 80, tween 20, tween 40, 
span 20 were supplied from Sisco research laboratories Pvt. Ltd. 
PEG 400, PEG200, propylene glycol, glycerol, PEG 600 were supplied 
from Sisco research laboratories Pvt. Ltd. Aerosil 200 was supplied 
from yarrow Chem product Pvt. Ltd. 
Solubility screening study 
The highest amount of drug solubility was determined by the shake 
flask method. 500 mg of nifedipine was added to 5 ml of each vehicle 
containing oil, surfactant, and cosurfactant. Then the mixture was 
shaken for 72 h to reach a uniform equilibrium state. It was 
centrifuged (Remi centrifuge equipment) for 10 min. at 5000 rpm. The 
supernatant was collected and diluted with phosphate buffer (pH 6.8). 
and quantified by spectrophotometrically at λmax of 238 nm [12, 13] 
Construction of pseudoternary phase diagram 
After the selection of higher drug solubility containing excipients 
(oil, surfactant, and cosurfactant), the pseudo ternary phase diagram 
was prepared at 1:1 and 1:2 ratio of the mixture of surfactants and 
co-surfactants. It determines the self-emulsifying region by taking 
the different ratios of oil and mixture of surfactant and co-surfactant 
[Oil: (S-COS) mix] from 9:1 to 1:9. The water was titrated into the 
mixture with constant stirring to observe the formation of o/w 
microemulsion The pseudo ternary phase diagram was constructed 
using software Chemix School (ternary software) [13]. 
Preparation of sedds formulation of nifedipine 
Different SEDDS formulations were prepared by using oil (Linseed oil), 
surfactant (tween 80) and co-surfactant (PEG 400). In each 
formulation, the amount of nifedipine (i. e-100 mg/10 ml) was 
constant. Each of the excipients was exactly weighed and gently mixed. 
Then the prepared mixtures were mixed with the help of a magnetic 
stirrer until a homogenous mixture was prepared. Then the prepared 
homogenous mixture was stored at 25⁰C for further studies [14]. 
Thermodynamic stability studies 
Thermodynamic stability study was done to observe any signs of 
phase separation, drug precipitation, creaming or cracking. All the 
smedds formulations were diluted with distilled water and 
centrifuged at 3500 rpm for 15 min. and check for any phase 
separation or clear emulsion. Then it was exposed to heating-cooling 
cycle (4 °C and 45 °C) and freeze-thaw stress cycle (-21 ° and+25 °C) 
with storage at each temperature for not less than 48 h. All the 
testing was done in triplicate and observes the extent of phase 
separation [15]. 
Self-emulsification time 
After thermodynamic stability testing, the stable formulations were 
taken for visual assessment self-emulsification efficiency. Self-
emulsification efficiency study was performed in the USP XXIV type 
II dissolution apparatus. 1 ml of each smedds formulation was added 
dropwise into 500 ml of buffer pH 6.8 and 1.2. and maintained at 37 
°C with a rotating speed of 50rpm. Then the time is noted for 
complete emulsification in two different media [16]. 
Drug content analysis 
The liquid-smedds formulation containing 10 mg equivalent drug 
was taken into 100 ml volumetric flask and diluted it with phosphate 
buffer pH 6.8 and analyzed by U. V. Visible Spectrophotometer at the 
λmax of 238 nm. 
Droplet size and zeta potential 
The droplet size of smedds formulation was determined using a zeta 
sizer Nano ZS (Malvern instrument, UK) dynamic light scattering 
particle size analyzer at a wavelength of 635 nm and a scattering 
angle of 90 °C at 25 °C. The formulation (0.1 ml) was diluting with 
100 times with double distilled water and sonicated for at least 30 
min. for the reduction of particle size of emulsion [17, 18]. 
Robustness to dilution 
All the formulations were taken for checking the robustness of 
emulsion in diluting with enzyme-free phosphate buffer ph6.8 
(simulated intestinal fluid) and 0.1N HCL (simulated gastric fluid). 1 
ml of each formulation was subjected to 50, 100, 500, 1000 fold 
dilution and kept them for 24h. After that, all the formulations were 
checked for any change in physical appearance i.e. coalescence of oil 
droplets, drug precipitation or phase separation [19]. 
In vitro diffusion studies of smedds 
The drug release experiment was performed in USP XXIII rotating 
paddle method using a dialysis bag method. The dialysis membrane 
was shocked in dialysis media (buffer pH6.8) for 12hr. at room 
temperature. After that, the liquid-smedds containing 100 mg of 
nifedipine were filled into soaked dialysis membrane and closed 
both sides of the dialysis membrane by using thread. Then it was put 
into the vessel containing 900 ml of phosphate buffer pH6.8 
carefully by which the dialysis membrane can easily rotate. The 
dissolution was performed at 37±0.5 °C for and rotated at 50 rpm 
for 120 min. At a specific time interval i.e. 15, 30, 45, 60, 75, 90, 105, 
120, the aliquot of 5 ml was withdrawn and filtered through a 0.45 
µm membrane filter. The same volume of the withdrawn amount 
should be replenished to maintain the sink condition of dissolution. 
The concentration of nifedipine was determined by 
spectrophotometrically at 238 nm. The dissolution of each 
formulation was performed in triplicate times. The dissolution 
profile of stable formulations was prepared and compared with the 
dissolution profile of the pure drug [20, 21]. 
Stability studies 
The liquid-smedds sample (LF9L) was selected for stability study at 
25±0.5˚C/60±5 % RH(relative humidity) and 40±0.5̊ C/75±5 % RH 
for 3 mo. It is filled in glass vials with a rubber stopper and then 
placed in Stability chambers. The physical appearance, drug content 
analysis, and particle size were evaluated with each 1-month 
interval [22]. 
Preparation of solid-smedds 
Solid self-emulsifying powder formulation was prepared by using 
adsorption to the solid carrier method, which is a very simple and 
reliable technique. The optimized formulation was taken for solid-
smedds preparation. Aerosil 200 was used in a different ratio to 
prepare solid smedds in the ratio of 0.50:1, 0.55:1, 0.65:1(adsorbent: 
liquid smedds). The adsorbent and liquid smedds were mixed in a 
porcelain dish until a uniform homogenized free-flowing powder 
was obtained. Then the powder was passed through sieve no. 120 
and dried at ambient temperature for further use. These 
formulations were evaluated for flow property. The developed 
optimized formulation was characterized for particle size analysis, 
percentage of drug content and in vitro dissolution study, scanning 
electron microscopy study(SEM), X-ray diffraction study(XRD), 
differential scanning calorimetry (DSC), and f. t. i. r study(Fourier 
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transform infrared spectroscopy). The evaluation study was carried 
out for optimized formulation and compared with pure drug. 
Flow properties of solid-smedds 
Flow properties of solid smedds were determined by Carr’s method. 
All the samples (0.50:1, 0.55:1, 0.65:1) were poured through the 
funnel in which the height of powder and its radius was obtained. 
The angle of repose was calculated using equation tan θ= H/r. The 
powder preparation having good flow property was selected as an 
optimized formulation and taken for particle size analysis and drug 
content analysis [23]. 
Drug content analysis of solid smedds 
SEDDS formulation (equivalent to 10 mg of the drug) was diluted 
with 100 ml of pH 6.8 phosphate buffer. It was diluted suitably with 
Phosphate buffer pH 6.8. It was analyzed using UV/vis. 
Spectrophotometer at 238 nm [24]. 
The particle size of solid smedds 
The particle size and zeta potential of the selected formulation were 
determined using Zetasizer Nano ZS(Malvern instrument, UV). The 
formulation was diluting with 100 times with distilled water then 
the emulsion was taken for analysis of particle size at 25 ⁰C at 90 ⁰C 
angle [24]. 
Solid state characterization of optimized solid self-
microemulsifying formulation 
The optimized solid-smedds was analyzed for ftir, DSC, XRD, and 
SEM analysis to investigate its solid-state properties. DSC 
thermogram was analyzed in Mettler Toledo DSC. F. t. i. r analyzes 
the compatibilities between drug and excipients present in the 
formulation. Each sample was scanned in a ftir spectrophotometer 
(Spectrum 2 FTIR spectrophotometer, Perkin Elmer) at a range of 
4000-400 cm-1. The XRD analysis of the sample was analyzed in an 
x-ray diffractometer (Rigaku Ultima IV, Japan) and SEM of self-
emulsifying powder was performed in the SEM instrument (Zeiss 
EVO 18 special edition) [25]. 
In vitro drug release 
The in vitro drug release study of solid smedds was performed in the 
USP XXIII dissolution apparatus at temperature 37±0.5 °C with a 
rotation speed of 50 rpm. The s-smedds formulations (equivalent to 
100 mg) were put into the vessel containing 900 ml buffer pH 
6.8(enzyme free simulated intestinal fluid). The entire dissolution 
was performed for 2 h. At predetermined periods, samples were 
withdrawn and diluted with phosphate buffer. Then the diluted 
sample was filtered using a 0.45 µm membrane filter and analyzed 
drug concentration on UV-spectrophotometer at λmax 238 nm. The 
same volume of fresh media was replaced after each interval of 
withdrawn of the sample to maintain the dissolution media constant. 
Stability studies 
The stability study of optimized s-smedds was performed at 40 °C±2 
°C and 75%±5% RH and 25±0.5˚C/60±5 % RH for three months. The 
samples were analyzed for physical appearance, particle size, and 
drug content analysis after each one-month interval. 
Statistical data analysis 
For the data analysis, a one-way analysis of variance (ANOVA) was 
used to compare the difference between solid-smedds, liquid smedds, 
and pure drugs by using mean value±standard deviation (SD). 
RESULTS 
Self-emulsifying preparation is a monophasic clear emulsion that 
contains oil, surfactant, and co-surfactant. For the analysis of 
solubility with nifedipine linseed oil, soybean oil, and almond oil 
were as oil, tween 60, tween 40, span 20 and tween 80 were as a 
surfactant and PEG 400, PEG 200, PPG, PEG 600 were taken as 
cosurfactants. The results of solubility in various vehicles were 
represented in fig. 1. From the analysis, it has been shown that 
nifedipine shows high solubility in linseed oil (61.23±0.95 mg/ml), 
Tween 80 (56.47±0.92 mg/ml), PEG 400 (49.98±0.15 mg/ml). 
Linseed oil is a natural and long-chain triglyceride oil, which have a 
good solvent capacity for dissolving drugs. Tween 80 is a hydrophilic 
nonionic surfactant that has a good solubilizing capacity and PEG 
400 as co-surfactant which lowers the interfacial tension. 
  
 
Fig. 1: Solubility studies of drug with various oils, surfactants, and cosurfactants. (mean±SD, n=3) 
 
Pseudo-ternary phase diagram 
Proper concentration of vehicles that produce stable emulsion must 
be essential to prepare self-emulsifying formulations. The pseudo 
ternary phase diagram defines the ternary phase behavior between 
components and provides proper concentration to prepare a stable 
emulsion. After water titration, the amount of water used was noted 
and developed the ternary phase diagram by using ternary software 
which has written in the method part. Fig. 2(a) and (b) represents 
the ternary phase diagram of smedds between castor oil, tween 80 
and PEG 400 (blue colored region indicate the region of self-
emulsification produced by SCOSmix 1:1 ratio and 1:2 ratio. The 
ternary diagram indicates that among both the SCOSmix ratio, a 1:1 
ratio provides a wide self-emulsification region. So this ratio was 
taken as the superlative ratio for preparation smedds. 
Preparation of smedds of nifedipine 
After the selection of oil, surfactant and co-surfactant and 
emulsification region, nine self-emulsifying formulations were 
prepared at 1:9 to 9:1 ratio where SCOSmix was 1:1 ratio. In all the 
mixture nifedipine (equivalent to 100 mg) was mixed and kept them 
for 24 h. at 25 °C. After 24 h., LF1L, LF2L, LF3L, LF4L, LF5L, LF6L, 
and LF9L were selected as stable because they showed no sign of 
phase separation and unstable formulations (LF7L and LF8L) are 
rejected as they showed phase separation. 
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Thermodynamic stability study 
Seven formulations showed stability i.e. there was no phase 
separation, the appearance of coalescence of oil droplets or any 
cracking appearance after keeping them for 24 h. of storage. Four 
formulations were remained stable after thermodynamic stability 
studies. But three formulations showed phase separation after 
freeze-thaw stress testing. So four formulations i.e. LF2L, LF3L, 
LF4L, and LF9L were taken for the evaluation study. Each test was 
done in triplicates. 
 
 
Fig. 2: Represents the ternary phase diagram between linseed oil, tween 80 and PEG 400 (green colored region indicate the self-
emulsification region produced by SCOSmix 1:1 ratio (a) and 1:2 ratio (b) 
 
Table 1: Observation of physical instabilities of sedds formulation during thermodynamic stability studies (mean±SD, n=3) 
Formulations Heating cooling cycle Centrifugation test Freeze-thaw stress cycle 
LF1L  ✓  ✓ × 
LF2L  ✓  ✓  ✓ 
LF3L  ✓  ✓  ✓  
LF4L  ✓  ✓  ✓ 
LF5L ✓  ×  × 
LF6L ✓ × × 
LF9L ✓ ✓ ✓ 
 
Droplet size and zeta potential analysis 
In the self-emulsification performance, the particle size of the 
emulsion is a crucial factor, because it determines the rate and 
extent of drug release as well as drug absorption. The particle size of 
formulations was in the nanometer range. LF9L showed a low 
particle size (249.1 nm) as compared to others. An increase in the 
ratio of the oil phase and a decrease in the S-Cosmix ratio resulted 
that the increase in particle size. Smaller in particle size increases 
drug release and delivers larger interfacial area across which drug 
can diffuse into the gastrointestinal fluids and thus increases drug 
absorption. 
Zeta potential of linseed oil formulation found to be-16.9 as a 
negative value which shows that due to the ionization of free fatty 
acids and glycols present in the oil and surfactants which improves 
formulation stability by preventing globule coalescence 
Drug content analysis 
From the drug content analysis, the result showed that three 
formulations, LF2L, LF3L, LF4L, and LF9L contained between 
69.25% to 79.05%. 
Robustness to dilution test 
Robustness to dilution study is performed to observe the effect of 
formulation on different pH. In this study, LF2L was unstable 
because it showed signs of phase separation when diluted with 
phosphate buffer (pH 6.8) and 0.1N HCL but LF3L, LF4L, and LF9L 
formulations remained stable for 24hr of dilution with both pH 6.8 
and 0.1N HCl. LF2L was rejected for further study due to the 
observation of phase separation. 
In vitro diffusion study of optimized smedds formulation 
From the robustness to the dilution test, LF2L was not selected for the 
in vitro drug diffusion study. The diffusion study of three formulations 
i.e. LF3L, LF4L, LF9L was performed for 2hr. using a dialysis bag 
method. The diffusion of the drug from prepared smedds and the pure 
drug was indicated in fig. 3. The result from in vitro diffusion studies 
was indicated that LF9L formulation showed more drug release of 
54% at 2 h. While pure drug release nifedipine only 6.72% at 2 h. LF3L 
and LF4L release 45.35% and 46.63%, which was less in comparison 
to LF9L formulation. Because these formulations contain more oil and 
less surfactant concentration which produces interruption with the 
release of the drug into the dissolution media. Drug release at 120 min 
was compared between LF9L formulation and pure drug using one 
way ANOVA. From the data analysis, it was suggested that, nifedipine 
release from LF9L formulation much faster and higher in comparison 
to the pure drug (*P<0.05). When SEDDS were exposed to aqueous 
media, it produces oil in water (o/w) microemulsion, having small 
globule size. The small globule size permitted drug release at a rapid 
rate from microemulsion. 
  
Table 2: Observation of the effect of sedds formulations on dilution at phosphate buffer pH 6.8 and 1.2. (mean±SD, n=3) 
Formulation code Phosphate buffer (pH6.8) 0.1N HCl Phosphate buffer (pH6.8) 0.1N HCl 
LF2L Phase separation (P. S.)  P. S. No drug precipitation (D. P.) No D. P. 
LF3L No P. S. No P. S. No D. P. No D. P. 
LF4L No P. S No P. S. No D. P. No D. P. 
LF9L No P. S No P. S. No D. P. No D. P. 
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Fig. 3: In vitro diffusion study of LF3L, LF4L, LF9L, and nifedipine (pure drug) (mean±SD, n=3) 
 
Stability study 
Based on all evaluation LF9L was selected for stability study to 
observe any physical and chemical changes within the formulation. 
The stability study was performed according to ICH guidelines for 3 
mo. Initially, the drug content (79.05%), particle size (249.1 nm) and 
zeta potential (-16.9mv) of LF9L were measured. After 3 mo, at 
accelerated condition((40±2̊C /75±5 %) the %drug content was 
reduced to 63% and at 25±2˚C/60±5 %, the %drug content was 69% 
which indicated that the instability of the formulation was observed 
due to decrease in assay content. After 3 mo, Particle size was 262.3 
nm and zeta potential was-22.3mv at the accelerated condition. 
Particle size and zeta potential were measured in zeta sizer and 
results were represented in fig. 4(a) and (b). 
  
 
Fig. 4: Particle size (a) and zeta potential (b) of LF9L after 3 mo at accelerated stability condition 
 
 
Fig. 5: Particle size (a) and zeta potential (b) of LF9S 
 
Preparation solid smedds of nifedipine 
For improving the stability, LF9L was formulated into solid smedds 
preparation by using adsorbent aerosil 200 at a different ratio. 
Three solid-smedds prepared i.e. LF9S (0.65:1), LF9S1 (0.55:1), 
LF9S2 (0.50:1) and taken for flow property study. 
Micromeretic study 
The flow property of three smedds powders was determined by 
calculating its angle of repose, tapped density, bulk density, 
Hausner's ratio, and Carr's index. Out of three formulations, LF9S 
has good flow property due to its value of angle of repose (22.3), 
Carr’s index (%) (15.6%) and Hausner's ratio (1.15). 
Particle size and zeta potential of LF9S 
After solidification, the particle size of LF9S was 208.3 nm and zeta 
potential was-25.8mv which was represented in fig. 4(a) and (b). 
Drug content analysis 
After solidification, the drug content analysis of LF9S was 85.26% 
which may be due to reduced particle size after solidification. 
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Solid-state characterization of LF9S 
FTIR spectra of nifedipine (pure drug) and LF9S was represented in 
fig. 6(A). It was shown that the characteristic peaks of the pure drug 
were 3328.70 cm-1 (N-H stretching of amine group), 2952.90 cm-1 
(C-H aliphatic stretching), 1677.73 cm-1 (C=O stretching of 
carboxylic group), 1622. cm-1 (C=C aromatic alkene stretching), 
1527.07 cm-1 (NO2 stretching) which were observed in the FTIR 
spectra of LF9S. So it was indicated that there were no chemical 
incompatibilities between drug and excipients present I formulation. 
The X-ray powder diffractometry (fig. 6(B)) of the pure drug shows 
some sharp and intense peak which indicated that the drug is 
present in the crystalline state. The presence of those intense small 
and sharp peaks was also observed in the physical mixture of drug 
and aerosil200 which showed that the drug present in the physical 
mixture is the semi-crystalline state. But in LF9S formulation, the 
sharp and intense peaks were disappeared which indicated that the 
drug present in the formulation is in an amorphous state. 
DSC thermogram of nifedipine (pure drug) and LF9S was presented 
in fig. 6(C). DSC of nifedipine shows a sharp endothermic peak at 
175 °C, corresponding to its melting points, indicating the crystalline 
nature of the drug. DSC of LF9S did not show any endothermic peak 
corresponding to its melting point. So it was concluded that the 
formulation was present as amorphous or solubilized form. 
 
 
Fig. 6: A. Fourier transform infrared spectrophotometer study of nifedipine(a) and LF9S(b), B. X-ray diffractometry study of Nifedipine(a), 
physical mixture of drug and aerosil 200(b), aerosil 200(c) and LF9S(d), C. Differential scanning calorimetry of nifedipine(a) and LF9S(b) 
 
SEM image of pure drug and formulation LF9S represented in fig. 7. 
At 5,000 magnification, the SEM image of the pure drug showed that 
the particles are seen very large and present as an unevenly shaped 
form. But in the formulation, at 20,000 magnifications, the drug 
particles were distributed uniformly throughout the solid carrier. 
There was a complete absence of crystal structure which 




Fig. 7: Scanning electron microscope photograph of nifedipine (a) and LF9S (b) 
 
In vitro drug release 
The drug release study of LF9S was performed and compared 
with the release pattern of pure drug and LF9L (smedds 
formulation). The in vitro dissolution profile of LF9S, pure drug 
and LF9 was represented in fig. 7. After 1 h of dissolution, LF9S 
released drugs more than 75%, in which LF9 and pure drug 
released only 17.22±0.26% and 2.54±0.04% respectively. At 120 
min. LF9S release drug more than 97% which was significantly 
higher than pure drug and LF9L (*P<0.05). Drug release from 
LF9S was faster due to increased surface area by use of 
adsorbent Aerosil 200, increasing the porosity of the formulation 
and may be due to transformation from crystalline to amorphous 
form. 
Stability study 
The stability of LF9S was performed according to ICH guidelines for 
3 mo. Initially, the drug content (85.26%), particle size (208 nm) and 
zeta potential (-18.7mv) were measured. After 3 mo, at 
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40±2˚C/75±5 %, the % drug content was reduced to 81.39% and at 
25±2˚C/60±5 %, the %drug content was to 84.67%. After 3 mo, the 
Particle size and zeta potential of LF9S were 249.4 nm and-32.2mv 
respectively (fig. 8). So there was no such significant difference 
observed in the assay study. After solidification, the stability is 
improved as a comparison to LF9 (liquid smedds). 
 
 
Fig. 8: In vitro diffusion profile of solid smedds (LF9S), smedds (LF9L) and Pure drug (nifedipine) (mean±SD, n=3) 
 
 
Fig. 9: Particle size (a) and zeta potential (b) of LF9S after 3 mo at accelerated stability condition 
 
DISCUSSION 
Liquid self-emulsifying drug delivery system of nifedipine was 
prepared by using oil, surfactant, and cosurfactant. Oil, surfactant, 
and co-surfactant were selected by solubility screening study. 
Linseed oil showed the highest solubility (61.23±0.95 mg/ml) and 
better than soybean oil (1.49±0.45) and almond oil (2.91±0.25). The 
surfactant itself an important element which stabilizes and help to 
solubilize drug. Nonionic surfactants were generally used due to less 
toxicity and high stability. It is better than ionic and amphiphilic 
surfactants. [3] So among all surfactants used tween 80 exhibited 
highest solubility (56.47±0.92) than tween 60 (32.34±0.96), tween 
40(41.34±0.88) and span 20 (8.87±0.18). The solubility of nifedipine 
with various cosurfactants has been investigated. PEG 400 was 
found (44.98±0.15) which was highest than PEG 200 (32±0.43), PPG 
(23.82±0.31) and PEG 600(26.10±1.01). According to solubility 
analytical studies, sedds formulations were developed by using 
linseed oil, tween 80 and PEG 400. A pseudo ternary phase diagram 
was developed by taking respective oil, surfactant, and cosurfactant. 
Surfactant and cosurfactant were mixed at 1:1 ratio and 1:2 ratios in 
which the mixtures of oil, surfactant, and co-surfactant were 
prepared at 1:9 to 9:1 ratio. From the pseudo-ternary phase 
diagram, SCOSmix (1:1) produced a reasonably wide self-
emulsification region than a 1:2 ratio. The efficiency of 
emulsification was good when the composition of the surfactant/co-
surfactant was taken at the same concentration. It was constructed 
based on the observations marked during titration after building the 
phase diagram of different formulations were selected at different 
point of the ternary phase. 
Different formulations were prepared at different concentrations of 
oil, surfactant, and cosurfactant. Formulations containing (70-80%) 
oil and SCOSmix (20%-30%) were rejected due to phase separation. 
Phase separation was initiated because the ratio of oil and SCOSmix 
contained in the formulation shown incompatibilities keeping after 
24h. The seven formulations were stable out of nine formulations. 
These formulations (9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 1:9) were exposed to 
heating cooling process, freeze thaw stress testing, centrifugation 
testing (table 1). Among those, three formulations showed phase 
separation after freeze-thaw stress testing because of the 
intolerance of excipients with a change in temperature. These three 
stable formulations were taken for particle size analysis, drug 
content analysis, and robustness to the dilution test. Robustness to 
dilution test was performed at different pH media pH 1.2 and 6.8 to 
mimic the in vivo conditions revealed no precipitation or phase 
separation indicating all the formulations were found to be robust 
towards different pH conditions [11]. So at both pH conditions LF3L, 
LF4L, LF9L shown stable i.e. no phase separation and drug 
precipitation after 24hr. But LF2L shown phase separation at both 
pH conditions. Because the robustness of formulation LF2L after 
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dilution was decreased at both pH conditions (table 2). As the 
discussed previously the particle size of LF9L was 249.1 nm and zeta 
potential-16.9mv which shown the least particle size than other 
formulation. The particle size of LF9L was decreased because the 
presence of the low amount of oil. As the concentration of SCOSmix 
is increasing the particle size is decreased. The smaller droplet size 
indicates more rapid absorption and improves the bioavailability of 
drug [26]. Due to its least particle size, the percentage of drug content 
is high and the percentage of drug release was more (54%) in 
comparison to other formulation and pure drug (6.72%). It may be 
due to proper composition between proportions of oil and SCOSmix 
which produced smaller droplet size with the highest drug content in 
the system. Due to its highest drug content, small droplet size and 
highest percentage of drug release LF9L is an optimized formulation 
for further study. It was exposed to different accelerated stability 
condition for 3 mo at 40 °C±2 °C and 75%±5% RH and 25±0.5˚C/60±5 
% RH. After 3 mo the percentage of drug content, particle size, and 
zeta potential analysis (fig. 9) were performed. It was seen that the 
percentage of drug content was reduced and the particle size (262.3 
nm) and zeta potential (-22.3mv) were increased due to the rise of 
instability in the formulation. The instability may be due to 
incompatibilities with the soft gelatin capsule shell and/or oxidation of 
lipids present in sedds [27]. 
So to improve stability, the solid smedds was prepared by using 
solid adsorbent aerosil 200 at a different ratio. Aerosill 200 is 
hydrophilic colloidal silicon dioxide which allows to attract and bind 
moisture to eliminate liquid bridges between solid particles that 
hinder powder flow [28]. Aerosil 200 was taken at a different ratio 
to determine the formulation of having good flow property. LF9S 
was selected due to its good flow property having angle of repose 
(22.3), Carr’s index (%) (15.6%) and Hausner's ratio (1.15). The 
selected solid smedds LF9S was taken for drug content analysis, 
particle size, and zeta potential analysis. The percentage of drug 
content was more due to complete and uniform adsorption of sedds 
into aerosil 200. The particle size and zeta potential were 208.3 nm 
and-25.8mv which was less in comparison to liquid sedds (fig. 5). 
From the f. t. i. r study, there were no incompatibilities between drug 
and excipients due to presence of same characteristics peaks in 
formulation and pure drug (fig. 6(A)). From the x-ray diffractometric 
study, the drug present in the formulation is in the amorphous state. 
It may be due to the uniform adsorptivity of the drug throughout the 
adsorbent (fig. 6(B)). The scanning electron microscopic study of 
formulation showed that the shape of the particle is uniform and 
distributed uniformly throughout the solid carrier (fig. 7). From the 
differential scanning calorimetry, LF9S was present in the 
formulation at an amorphous state because it showed a straight line 
within a melting point (175 °C) (fig. 6(C)). The in vitro dissolution 
study was performed for 2h. at pH 6.8 dissolution media. At 120 min. 
LF9S release drug more than 97% which was significantly higher 
than pure drug and LF9. Drug release from LF9S was faster due to 
increased surface area by use of adsorbent (fig. 8). Aerosil 200, 
increasing the porosity of the formulation and may be due to 
transformation from crystalline to amorphous form. After an in vitro 
dissolution study, LF9S was taken for accelerated stability study for 
a minimum period of 3 mo at 40 °C±2 °C and 75%±5% RH and 
25±0.5 °C/60±5 % RH. The drug content analysis, particle size, and 
zeta potential analysis was performed. The particle size and zeta 
potential were 249.4 nm and-32.2mv. Which describe that LF9S lied 
within micron range. There was no such significant difference 
observed in assay study, particle size and zeta potential analysis. 
After solidification, the solubility as well as stability was improved 
as a comparison to LF9L (liquid smedds) formulation. 
CONCLUSION 
Solid-self emulsifying drug delivery system of nifedipine was 
successfully prepared by using linseed oil as oil part, Tween 80 as a 
surfactant, PEG 400 as co-surfactant and Aerosil 200 as adsorbent. 
Nine liquid self-emulsifying formulations were prepared at a 
different ratio. The best self-emulsifying formulation (LF9L) which 
was optimized by different evaluation process and stability study. At 
accelerated condition after three months, the percentage of drug 
content was reduced which indicated that the formulation was in 
instability condition. So to improve stability of the liquid self-
emulsifying formulation, it was converted to s-sedds by adsorption 
to solid carrier technique using aerosil200. After solidification, drug 
content was more than 85.26% and the particle size was 208 nm. 
From the in vitro dissolution study, LF9S release 98.70%, which was 
highest among LF9L and pure drug. From the FTIR study, it was 
indicated that there were no incompatibilities between drug and 
excipients. From the DSC and XRD study, it was shown that the drug 
was present in the formulation as an amorphous form. From the 
stability analysis, it was seen that no significant difference was 
observed during drug content analysis. Thus it was concluded that 
solid SEDDS formulation is capable to enhance solubility and 
dissolution of poorly water-soluble drugs like nifedipine by using 
aerosil 200 which improves therapeutic performance. 
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